Institutional dossier
The documented history of Recursion Pharmaceuticals: chronology, people, research, capital and compute, and governance. Every statement opens its source and its limits.
Records dated 2013-11 to 2024-11-20 · 0 undated
7 claims · 4 sources · 7 not editorially accepted. The counts describe this selection. They do not measure completeness or independent confirmation.
Scope, evidence and limits
Description: Recursion Pharmaceuticals, Inc.
The records are grouped automatically. No human inspection of the selected claims, source paths or framing is recorded for this dossier. Each source passage shows how it was checked.
The dossier is computed from existing records. It is not a continuous history of the institution, and a missing record does not mean that an event or relationship did not happen. The chronology uses the dates of events and reports, not the date the public could first have known of them. Later sources can describe earlier events.
Select any statement to see its exact claim, qualification, date note, evidence passage, location in the source, source version and review status. The description above is Selekoa’s stored description of the institution, based on these sources:
- Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
- Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
Connected institutional dossiers
Institutions linked by a documented relationship. Each keeps its own chronology and evidence. When units combine, their earlier records stay separate.
Chronology
Records about the institution itself and documented changes to its frameworks, by year. Expand a year to read the claims. People’s other institutional records and related documents have their own sections. Where a date gives only the year or month, the order within it is unknown.
2013Record year · 2 claims
- Recursion's IPO prospectus (15 April 2021) names Christopher Gibson as the company's co-founder.Chris Gibson → co-founded → Recursion PharmaceuticalsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
Co-founding is as the prospectus states it; the same text names Blake Borgeson as a co-founder too, and no complete founder roster is implied.
Founding month as stated in Recursion's IPO prospectus of 15 April 2021 ("since the company's founding in November 2013"; its Corporate Information dates the company's formation to November 2013); no day is given and no separate date of Gibson's participation is stated.
- Recursion's IPO prospectus (15 April 2021) states that the company was formed in Delaware as a limited liability company in November 2013 under the name Recursion Pharmaceuticals, LLC.Recursion Pharmaceuticals → is stated to have been founded in → November 2013 Inspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
The prospectus states a formation month as a limited liability company; it does not establish a founder roster, which other records cover.
Month as stated by the prospectus; no day is given. The prospectus also dates a conversion to a Delaware corporation to September 2016.
2021Record year · 2 claims
- Recursion's IPO prospectus (15 April 2021) names Christopher Gibson as its Chief Executive Officer and states that he had held the role since the company's founding in November 2013.Chris Gibson → held role at → Recursion PharmaceuticalsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
A historical role snapshot. The record does not establish the end of the role or any later title.
A role stated in the prospectus of this date; the start as stated (November 2013) is the company's statement. No continuing appointment is implied.
- Recursion announced on 7 December 2021 a collaboration with Roche and Genentech in neuroscience and an oncology indication, under which it would receive an upfront payment of $150 million, and stated that Roche and Genentech may initiate up to 40 programs, each of which could yield more than $300 million in milestones if successfully developed and commercialized.Recursion Pharmaceuticals → announced a partnership with → RocheInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
Announced terms as Recursion states them. The milestone figures are conditional and per programme; they are not totalled, and the record does not establish payments received. Genentech is a party with Roche (the release names Genentech as a member of the Roche Group).
Date of Recursion's press release.
2023Record year · 2 claims
- Recursion announced on 12 July 2023 a $50 million investment by NVIDIA, executed as a private investment in public equity (PIPE).NVIDIA → announced investment in → Recursion PharmaceuticalsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Stage: announced · exact USD 50,000,000 · transaction
Qualification and date notes
Recursion's announcement; the record does not establish the number of shares, the price or the settlement. The amount is the stated amount of this PIPE investment by NVIDIA, not a valuation.
Date of Recursion's press release.
- Recursion announced on 12 July 2023 plans to develop AI foundation models for biology and chemistry which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services, with possible release on NVIDIA's BioNeMo.Recursion Pharmaceuticals → announced a partnership with → NVIDIAInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
An announced collaboration and stated intentions ("plans", "intends", "possible"); the record does not establish that any model was trained, licensed or released.
Date of Recursion's press release.
2024Record year · 1 claims
- Recursion stated on 20 November 2024 that its business combination with Exscientia had been completed, with Exscientia becoming a wholly owned subsidiary of Recursion.Recursion Pharmaceuticals → acquired → ExscientiaInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
Recursion's statement of completion, filed as an exhibit to its Form 8-K; the record does not state the consideration paid at closing or the legal steps (the 2024-08-08 announcement describes a court-sanctioned scheme).
Date of Recursion's press release reporting completion. The Form 8-K to which the release is Exhibit 99.3 (accession 0001601830-24-000217, filed 2024-11-20) gives 2024-11-19 as its period of report (date of earliest event reported), under Item 2.01 Completion of Acquisition or Disposition of Assets, as its EDGAR filing index page shows (retrieved 2026-10-30); completion may therefore have taken effect on 19 November 2024. The 8-K body was not retrieved (HTTP 403).